**Technology, Media & Telecom**

**Advanced Micro Devices**

*7nm Growth Thesis Intact For ’19/’20; Near-Term GPU Headwind Larger Than Feared*  

**The Cowen Insight**  
AMD posted a mixed 3Q and delivered weak 4Q guidance. Despite near-term GPU and console weakness in Q4, our long-term fundamental thesis remains intact. We believe AMD remains positioned for sustainable x86 PC and server CPU share gains as we enter a period where the company will have its first manufacturing advantage against Intel in recent memory.

Matthew D. Ramsay  
415 646 7373  
matt.ramsay@cowen.com

**Technology, Media & Telecom**

**DXC Technology**

*Risk Reward May Offer Attractive Trade Despite Elevated Uncertainty*  

**The Cowen Insight**  
The risk reward on DXC shares seems hard to ignore at ~8x FY20 EPS. There is elevated uncertainty into its F2Q results/Analyst Day and the question of whether it can ultimately turn the top line persists, but we see no apparent change to the crux of this cost-driven story. We await clarity but see an attractive discount post steep correction for more risk tolerant investors; PT $90.

Bryan C. Bergin, CFA  
646 562 1369  
bryan.bergin@cowen.com
Capital Goods/Industrials

Ingersoll-Rand plc
Q3 Affirms Our Bullish Thesis.

**THE COWEN INSIGHT**
Q3 results were strong, order momentum remains healthy, capital allocation plans seem prudent, and initial C19 color is upbeat. These differentiated points from other industrials should drive an upward re-rating of IR’s stock.

---

**Technology, Media & Telecom**

ServiceNow
Solid 3Q Billings Beat Led By Fed; Raises FY Guidance for First Time This Year

**THE COWEN INSIGHT**
NOW delivered a solid 3Q with sub billings growth of 34% cc above our 31% estimate, and high-end of FY18 growth guide was raised from 31% to 32% cc. NOW had its strongest federal qtr ever and was 20% of net new ACV. Emerging products had a strong qtr as well and we see a long runway ahead as NOW expands into a more strategic Digital Workflow Platform for large enterprises. Raise PT to $210.

---

Other Research Today

Consumer

Alaska Air Group
RASM Inflection Is Finally Here

**THE COWEN INSIGHT**
Alaska Air Group reported 3Q18 results ahead of consensus estimates. Alaska’s RASM outlook is now firmly positive and could wind up being the best sequential improvement in the industry. Alaska Airlines needs to continue to focus on improving margins in 2019.
Health Care

Alexion Pharmaceuticals
Business Is Humming; We Are Hopeful Ultomiris Will Relieve Competitive Concerns

OUTPERFORM (1)

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: ALXN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$165.00 (Prior $163.00)</td>
</tr>
<tr>
<td>Price (10/23/2018)</td>
<td>$123.00</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$27,411.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$5.86</td>
<td>$7.60</td>
<td>$8.40</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$7.19</td>
<td>$8.10</td>
</tr>
<tr>
<td>Consensus</td>
<td>$5.86</td>
<td>$7.25</td>
<td>$8.51</td>
</tr>
</tbody>
</table>

THE COWEN INSIGHT

ALXN’s Q3 revenue and EPS beat consensus, prompting an increase in 2018 guidance, as Soliris’s launch in gMG bested its prior launches in aHUS and PNH. Ultomiris is on track for a February 2019 approval. We are optimistic that a rapid conversion onto Ultomiris will increase investors’ appreciation for ALXN’s prospects for long-term revenue growth.

Phil Nadeau, Ph.D.
646 562 1336
phil.nadeau@cowen.com

Consumer

Allegiant Travel Company
Operational Improvement At Airline Continues

MARKET PERFORM (2)

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: ALGT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$132.00 (Prior $142.00)</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$115.44</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$1,842.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$9.68</td>
<td>$9.46</td>
<td>$10.45</td>
</tr>
<tr>
<td>Consensus</td>
<td>$9.55</td>
<td>$10.13</td>
<td>-</td>
</tr>
</tbody>
</table>

THE COWEN INSIGHT

Allegiant Travel's 3Q18 results were aided by a lower than expected tax rate. Underlying operational performance continues to improve despite fleet transition. Allegiant will completely retire the MD80s after the Thanksgiving travel period and become a full A320-family operator.

Helane Becker
646 562 1399
helane.becker@cowen.com

Capital Goods/Industrials

Amphenol Corporation
Impressive In The Face Of Palpable Fear Elsewhere

OUTPERFORM (1)

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: APH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$110.00</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$83.57</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$25,100.5</td>
</tr>
</tbody>
</table>

THE COWEN INSIGHT

APH delivered a very strong operational quarter with solid contribution from nearly all its end markets. Auto, while slightly below model was still robust and commentary doesn’t suggest the huge declines many feared - as customer diversity and content growth continue. This is the type of market that will likely reward those that minimize volatility, something APH does well.

Joseph Giordano, CFA
646 562 1405
joseph.giordano@cowen.com
Technology, Media & Telecom

AT&T

Entertainment Results Suggest a Challenging Balancing Game

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Price Target</th>
<th>Price (10/24/2018)</th>
<th>Market Cap (MM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NYSE: T</td>
<td>$34.00</td>
<td>$30.36</td>
<td>$220,717.2</td>
</tr>
</tbody>
</table>

**EPS $**

<table>
<thead>
<tr>
<th></th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$3.05</td>
<td>$3.49</td>
<td>$3.55</td>
</tr>
<tr>
<td>Consensus</td>
<td>$2.91</td>
<td>$3.54</td>
<td>$3.65</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

T reported mixed headline 3Q18 results with solid Wireless, mixed WarnerMedia, but weak Ent. results. Downside Ent. margins and DTV Now adds suggest a challenging balancing game between profits and uptake. While we don’t see the stock turning around in the NT, the sell-off felt overdone while making good on promises of flat Ent. EBITDA and +$25B FCF in 2019 could ultimately drive material upside.

Colby Synesael
646 562 1355
colby.synesael@cowen.com

Link to Full Note

Capital Goods/Industrials

Boeing Company

Strong Q3 Bolsters Extended Cash Ramp

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Price Target</th>
<th>Price (10/24/2018)</th>
<th>Market Cap (MM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NYSE: BA</td>
<td>$445.00</td>
<td>$354.65</td>
<td>$203,749.4</td>
</tr>
</tbody>
</table>

**EPS $**

<table>
<thead>
<tr>
<th></th>
<th>2018E</th>
<th>2019E</th>
<th>2020E</th>
<th>2021E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$15.20</td>
<td>$18.00</td>
<td>$20.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Consensus</td>
<td>$14.65</td>
<td>$17.78</td>
<td>$20.88</td>
<td>$23.40</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

Healthy but messy Q3 showed impressive commercial execution bolstering our thesis that BA’s favorable production set up augurs cash flow ramp to ~$35/sh. by 2021. With a 7.9% 2019 CF yield, it’s our #1 pick for a $445 PT.

Cai von Rumohr, CFA
617 946 3942
cai.von-rumohr@cowen.com

Link to Full Note

Health Care

Boston Scientific

BSX Extends Its Top-Line Growth Hot Streak in 3Q; We Like the Outlook for 2019

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Price Target</th>
<th>Price (10/24/2018)</th>
<th>Market Cap (MM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NYSE: BSX</td>
<td>$42.00</td>
<td>$35.68</td>
<td>$49,342.8</td>
</tr>
</tbody>
</table>

**EPS $**

<table>
<thead>
<tr>
<th></th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$1.26</td>
<td>$1.38</td>
<td>$1.55</td>
</tr>
<tr>
<td>Consensus</td>
<td>$1.26</td>
<td>$1.40</td>
<td>$1.58</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

BSX again showed stellar organic sales growth in 3Q – this time, 8.7%, which is an unquestionably solid number that topped our expectation by 140 bps. The company delivered across all of its businesses, with Cardiovascular up 7.2% organically, MedSurg up 11.0% and Rhythm & Neuro up 8.3%. Reported sales reflect the 140-bp Fx headwind that developed intraquarter vs. the prior “immaterial” forecast.

Joshua Jennings, M.D.
646 562 1333
josh.jennings@cowen.com

Link to Full Note
Consumer

**Callaway Golf**

Callaway Continues To Hit It Long and Straight

**THE COWEN INSIGHT**

Q4 guidance is below consensus and until we have a better understanding of sell in dynamics in 1H:19 we would remain on the sidelines. The ability to expand operating margin beyond what is now a peak level will be critical for future growth. Reiterate $24 price target.

John Kernan, CFA
646 562 1324
john.kernan@cowen.com

Energy

**U.S. Liquefied Natural Gas**

Lng Industry 3Q18 Preview

**THE COWEN INSIGHT**

GLNG results should benefit from lng carrier rates in 3Q18, which have climbed to multi-year highs, while Tortue FID remains an important near-term catalyst that may not be priced into the stock. LNG should provide an update on new train startups on its quarterly call; we forecast first lng late 2018.

Jason Gabelman
646 562 1309
jason.gabelman@cowen.com

Technology, Media & Telecom

**Citrix Systems**

Delivers 3Q Upside, Provides Healthy Initial Outlook for 2019

**THE COWEN INSIGHT**

As previewed, CTXS reported upside to consensus 2Q expectations, with particular strength in Workspace Services and enterprise networking. Mgmt also provided healthy initial 2019 guidance. While we continue to expect the subscription transition to be gradual, we retain our positive bias on the shares at current levels.

Gregg Moskowitz, CFA
646 562 1390
gregg.moskowitz@cowen.com
Energy

Core Laboratories N.V.
3Q18 Earnings at a Glance

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: CLB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$100.00</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$91.98</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$4,066.7</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

**Negative:** 3Q EPS of 64c at low end of guided range and 4Q guided to 48-54c below 58c consensus as CLB sees flattish international activity and a decline in U.S. completions. While CLB had discussed 4Q weakness in an Oct 4th 8-K, no specific guidance was provided. 2019 tax rate could be 20% vs guided 15% in 4Q and our modeled 15% in 2019. 8:30 AM Call.

Marc Bianchi, CFA
646 562 1393
marc.bianchi@cowen.com

Capital Goods/Industrials

Covenant Transportation Group
Recent Acquisition Helps Drive 3Q

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: CVTI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$32.00 (Prior $36.00)</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$25.26</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$463.4</td>
</tr>
<tr>
<td>EPS $</td>
<td>2017A</td>
</tr>
<tr>
<td>Cowen</td>
<td>$0.86</td>
</tr>
<tr>
<td>Consensus</td>
<td>$0.86</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

CVTI reported a 3Q top and bottom-line beat. Early returns on CVTI’s Landair acquisition are positive, with mgmt highlighting salesforce synergies which may result in increased shipper wins. Mgmt expects a strong peak season and 4Q. We maintain our Market Perform rating on the stock as we remain somewhat concerned about the broader market weakness the past month.

Jason H. Seidl
646 562 1404
jason.seidl@cowen.com

Capital Goods/Industrials

Echo Global Logistics
ECHo’s 3Q: Another EPS and EBITDA Beat

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: ECHO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$40.00 (Prior $42.00)</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$24.25</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$692.3</td>
</tr>
<tr>
<td>EPS $</td>
<td>2017A</td>
</tr>
<tr>
<td>Cowen</td>
<td>$0.86</td>
</tr>
<tr>
<td>Consensus</td>
<td>$0.86</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

ECHo reported an EPS and EBITDA beat, with a top line that slightly missed our estimates. Mgmt continues to sound confident in ECHO’s growth, proprietary technology development, and the broader freight marketplace. While we maintain our Outperform rating on the Chicago-based broker, we note the next quarter could prove challenging for the company.

Jason H. Seidl
646 562 1404
jason.seidl@cowen.com

This report is intended for jschipper@conestogacapital.com. Unauthorized redistribution of this report is prohibited.
Technology, Media & Telecom

**Equifax**

EFX 3Q18 Quick Take: Growth Dissapoints

<table>
<thead>
<tr>
<th>OUTPERFORM (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symbol</td>
</tr>
<tr>
<td>Price Target</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

EFX reported disappointing 3Q results. Organic cc revenue growth decelerated to 2%, below our estimate and company guidance. Consequently EFX lowered its 2018 outlook now expecting cc revenue growth of 2.2%-2.7%. While the deceleration is credibly explained (share loss is not the primary driver), it pushes our growth acceleration thesis out and will weigh heavily on the stock tomorrow in our view.

George Mihalos  
646 562 1360  
george.mihalos@cowen.com

**Link to Full Note**

Technology, Media & Telecom

**F5 Networks**

FY4Q18: Another Step Forward

<table>
<thead>
<tr>
<th>OUTPERFORM (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symbol</td>
</tr>
<tr>
<td>Price Target</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPS $</th>
<th>2019E</th>
<th>2020E</th>
<th>2021E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$10.96</td>
<td>$12.09</td>
<td>$13.74</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$11.89</td>
<td></td>
</tr>
<tr>
<td>Consensus</td>
<td>$10.43</td>
<td>$11.34</td>
<td>$10.10</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

A second straight quarter of encouraging operating results and outlook with building momentum in F5’s Software, Security and Cloud business, FY4Q18 reinforced our positive view of oper model and shares. We continue to see solid LT underlying demand drivers with F5 well-positioned to address Cloud transformation. We have increased our PT to $196 from $186 and reiterate our Outperform rating.

Paul Silverstein  
646 562 1340  
paul.silverstein@cowen.com

**Link to Full Note**

Capital Goods/Industrials

**General Dynamics**

Nordam Glitches Delay G500/600 Build

<table>
<thead>
<tr>
<th>OUTPERFORM (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symbol</td>
</tr>
<tr>
<td>Price Target</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$9.95</td>
<td>$11.15</td>
<td>$12.20</td>
<td>$13.65</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$11.10</td>
<td>-</td>
<td>$13.70</td>
</tr>
<tr>
<td>Consensus</td>
<td>$9.81</td>
<td>$11.11</td>
<td>$12.28</td>
<td>$13.85</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

GD’s 8% selloff on uninspiring Q3 & Gulfstream slip looks overblown. Its defense uptrend is intact, bizjet demand improving, and it’s recovering from G500 nacelle delay glitches. The stock has support from a 7.2% cash flow yield with expected firming Gulfstream book-bill in Q4.

Cai von Rumohr, CFA  
617 946 3942  
cai.von-rumohr@cowen.com

**Link to Full Note**
Technology, Media & Telecom

E-Commerce
3Q18: SMID-Cap Internet Earnings Preview

THE COWEN INSIGHT
In this note we preview 3Q18 results for 6 names in our coverage universe including GRPN, YELP, CRTO, TRUP, CISN and LEAF. We expect most reports to take place in late October / early November.

Thomas Champion
646 562 1365
thomas.champion@cowen.com

Technology, Media & Telecom

Hilton Worldwide Holdings
Q3: Strong Pipeline, But Macro & FCF Commentary Disappointing; PT To $74

OUTPERFORM (2)
Symbol NYSE:HLT
Price Target $74.00 (Prior $81.00)
Price (10/24/2018) $63.82
Market Cap (MM) $18,927.1

THE COWEN INSIGHT
Units were solid at +6.7%; however, weaker 2H RevPAR felt glossed over and played into macro concerns. FCF y/y in 19E may also be modest, with less capital returns on HNA lap. Loyalty margins also appeared to trend down again. All-in, cut EBITDA <1%, but more conservative on FCF to $4.13 20E (vs. $4.50). Nevertheless, Outperform on strong pipeline, reasonable valuation. PT $74 (vs. $81) = 18X FCF.

Kevin Kopelman, CFA
646 562 1348
kevin.kopelman@cowen.com

Health Care

La Jolla Pharmaceutical
Q3 Revenues In-Line With Expectations, Giapreza Continues Steady Uptake

OUTPERFORM (1)
Symbol NASDAQ:LJPC
Price Target $50.00 (Prior $47.00)
Price (10/24/2018) $15.23
Market Cap (MM) $399.5

THE COWEN INSIGHT
LJPC reported Q3 Giapreza revenue of $3.5MM, in line with our $3.5MME and consensus of $3.3MME. La Jolla continues to work to get Giapreza on hospital formularies and in the electronic medical systems that enable prescribing. We are hopeful for an inflection in revenue in 2019 once access is secured and remain at Outperform.

Phil Nadeau, Ph.D.
646 562 1336
phil.nadeau@cowen.com

This report is intended for jschipper@conestogacapital.com. Unauthorized redistribution of this report is prohibited.
Technology, Media & Telecom

Semiconductors

Hynix’s CQ3:18 Earnings = Another Negative Read On Semis

THE COWEN INSIGHT

Hynix articulated an uninspiring demand outlook, and the largest surprise to us was commentary indicating server DRAM will remain weak until 2H:19. Concurrently, a challenging backdrop for smartphones and low-end PCs is causing elevated NAND inventory and expected NAND ASP declines through CQ1:19. Server/PC commentary reads negative for STX, MU & WDC; capex commentary is an overhang for ICHR/UCTT.

Karl Ackerman, CFA
415 646 7219
karl.ackerman@cowen.com

Level 5.0

Capital Goods/Industrials

Melexis NV

Guidance Disappoints - Dragged Down by Macro Auto and Inventory Management

THE COWEN INSIGHT

Melexis 3Q18 results came in slightly below estimates on the topline, with GM driving EPS upside vs. our estimates. Implied guidance of ~€140.2mn for 4Q18 came in below our €150mn prior expectations, as auto and non-auto customers look to manage inventory. Valuation looks more compelling here, but we see Auto Tech names underperforming into Spring 2019 on tariff concerns.

Jeffrey Osborne
646 562 1391
jeffrey.osborne@cowen.com

Level 5.0

Technology, Media & Telecom

Microsoft

A Good Start to FY19; Reiterate Outperform

OUTPERFORM (1)

THE COWEN INSIGHT

MSFT delivered another quarter of revenue and margin upside, with strength across all three segments. MSFT’s fundamentals remain strong overall, and we reiterate our Outperform and $117 price target.

Gregg Moskowitz, CFA
646 562 1390
gregg.moskowitz@cowen.com

Level 5.0
Capital Goods/Industrials

Norfolk Southern Corp.
Ahead of Schedule, Longer Term Update Coming in February

OUTPERFORM (1)

Symbol NYSE: NSC
Price Target $194.00 (Prior $189.00)
Price (10/23/2018) $156.97
Market Cap (MM) $43,956.3

THE COWEN INSIGHT
NSC delivered another strong quarter, beating our and Street estimates top to bottom. EPS and OR were third-quarter records. The company has begun implementing an evolutionary operating plan pillared on “clean sheeting” and aspects of PSR and intends to provide an updated strategic vision in February. Reiterating Outperform and raising PT to $194 from $189.

Jason H. Seidl
646 562 1404
jason.seidl@cowen.com

Capital Goods/Industrials

Northrop Grumman
Q3 Beat & Raise; FAS Optics Restrain 2019

MARKET PERFORM (2)

Symbol NYSE: NOC
Price Target $350.00
Price (10/24/2018) $285.86
Market Cap (MM) $49,774.9

THE COWEN INSIGHT
NOC’s 6% selloff following a Q3 beat & raise likely reflects yesterday’s nasty tape and non-cash pension optics paring 2019 GAAP EPS. However, NOC’s moderated 14.5x 2019 TEV/EBITDA still is a peer high, which looks fairly priced.

Cai von Rumohr, CFA
617 946 3942
cai.von-rumohr@cowen.com

Energy

Oceaneering International
3Q18 Earnings at a Glance

MARKET PERFORM (2)

Symbol NYSE: OII
Price Target $27.00
Price (10/24/2018) $21.18
Market Cap (MM) $2,086.9

THE COWEN INSIGHT
Modest Negative: Slight EBITDA beat, but guidance for 2018 EBITDA to be at the ‘lower half’ of $140-160MM range implies downside to 4Q. Lack of formal 2019 guide may disappoint some, but management does see increased activity levels in each segment led by Subsea Products. 11AM Call.

Marc Bianchi, CFA
646 562 1393
marc.bianchi@cowen.com
Consumer

Restaurant Brands International
We Remain Optimistic on the Path Ahead

OUTPERFORM (1)
Symbol NYSE: QSR
Price Target $74.00
Price (10/24/2018) $56.22
Market Cap (MM) $26,368.5

THE COWEN INSIGHT
We believe 3Q’s global store opening slowdown is transitory, while in-line to better than expected Tim’s Canada comps (~50% of adj. EBITDA) should be enough to offset what could be continued softness at BK U.S. (~20-25% of adj. EBITDA). We want to highlight that we model a $55M impact to 4Q adj EBITDA related to ASC 606 revenue recognition for franchise fees, though importantly this is non-cash.

Andrew M. Charles, CFA
646 562 1332
andrew.charles@cowen.com

Health Care

Sarepta Therapeutics
3Q18: Exondys Growth Continues As Pipeline Continues to Expand And Progress

OUTPERFORM (1)
Symbol NASDAQ: SRPT
Price Target $178.00
Price (10/24/2018) $123.04
Market Cap (MM) $8,175.1

THE COWEN INSIGHT
SRPT reported 3Q18 financials, with Exondys revenues very slightly below consensus, but still on track for FY18 guidance. SRPT continues to progress and add on to its now deep, diversified and promising pipeline of neuromuscular/CNS gene therapy programs which should drive forward value. We are optimistic on the microdystrophin GT program, and potential of the rest of the gene therapy pipeline.

Ritu Baral
646 562 1379
ritu.baral@cowen.com

Technology, Media & Telecom

Silicon Laboratories
Solid Results; Ugly Tape

OUTPERFORM (1)
Symbol NASDAQ: SLAB
Price Target $107.00 (Prior $125.00)
Price (10/24/2018) 77.46
Market Cap (MM) 3,342.3

THE COWEN INSIGHT
Silicon Labs reported strong 3Q results but issued 4Q guidance (not surprisingly) below consensus - better than feared following bellwether Texas Instrument’s weak outlook. Though macro is clearly weighing on the group, we believe long-term Silicon Lab’s IoT portfolio and ramping Infrastructure business should drive well-above peer growth. We remain Outperform with a lowered $107 target.

Matthew D. Ramsay
415 646 7373
matt.ramsay@cowen.com

Link to Full Note
Technology, Media & Telecom

Software

Take-Aways From Tableau Conference; Data Points On the Broader Analytics Market

THE COWEN INSIGHT

We attended Tableau’s annual users conference in New Orleans this week. There were 17k in attendance, up ~20% Y/Y vs. the 14k last year. There were no major new product announcements and we came away with the sense that business trends are stable with no meaningful change in directional drivers. Trading at ~7.5x EV/CY19E Recurring Revenue, we maintain our Market Perform rating.

J. Derrick Wood, CFA
415 646 7370
derrick.wood@cowen.com

Consumer

Specialty Retail

Cowen Pulse On Retail: Cold Snap Driving Apparel Traffic; Helping Seasonal

THE COWEN INSIGHT

October Week 3 total U.S. retail traffic decreased -0.8% y/y vs. -1.7% y/y last week. Apparel traffic increased +1.8% y/y vs. last week’s +0.4% y/y. On a 2-year basis, total U.S. retail traffic was down -4.6% vs. last week’s -7.0%. October Week 3 temperatures were -8.4° colder vs. LY but -1.8° below average.

Cowen Retail Team
646 562 1010
retail@cowen.com

Consumer

Spirit Airlines

Initiatives Driving Unit Revenue Higher

MARKET PERFORM (2)
Symbol NYSE: SAVE
Price Target $46.00
Price (10/24/2018) $47.69
Market Cap (MM) $3,255.0

THE COWEN INSIGHT

Spirit Airlines reported 3Q18 revenue and earnings ahead of consensus, and in line with our estimates. Management forecast 4Q18 unit revenue growth of ~6%, which is above our expectations despite higher capacity growth. The unit revenue outlook is driven by strong close-in bookings, changes to the network and continued growth in ancillary fees.

Helane Becker
646 562 1399
helane.becker@cowen.com

Link to Full Note
Energy

SunPower

3Q18 Preview: Tariff Headwinds Abate; NGT Ramping; Balance Sheet Set to Improve

OUTPERFORM (1)
Symbol NASDAQ: SPWR
Price Target $10.00
Price (10/24/2018) $6.42
Market Cap (MM) $905.2
Cowen $(0.24) $(0.80) $(0.02) $0.06

THE COWEN INSIGHT
We are constructive on SunPower heading into earnings. The company received an exemption from the Section 201 tariffs for its IBC modules. This should help SunPower to better compete on price and drive higher utilization. The NGT ramp should further this competitive position given higher efficiencies and lower manufacturing costs. B/S delevering should continue w/ monetization of lease portfolio.

Jeffrey Osborne
646 562 1391
jeffrey.osborne@cowen.com

Energy

TechnipFMC

3Q18 Earnings at a Glance

OUTPERFORM (1)
Symbol NYSE: FTI
Price Target $37.00
Price (10/24/2018) $27.24
Market Cap (MM) $12,380.6

THE COWEN INSIGHT
Neutral: EBITDA beat with solid orders, but 2018 Subsea margin guide unchanged could imply a significant drop in 4Q. Lack of 2019 guide (now scheduled for Dec 12th) may disappoint as some expected at 3Q update. Cash generation turned positive, but momentum will need to continue. 8AM call.

Marc Bianchi, CFA
646 562 1393
marc.bianchi@cowen.com

Capital Goods/Industrials

Tesla

25% Auto GM & Improved W/C Impress, But Competition & Valuation Concerns Remain

UNDERPERFORM (3)
Symbol NASDAQ: TSLA
Price Target $250.00 (Prior $200.00)
Price (10/24/2018) $288.50
Market Cap (MM) $49,216.1
Cowen $(8.63) $(0.92) $10.62 $11.23
Prior $(6.15) $1.43 $8.42
Consensus $(8.61) $(7.00) $5.56 $11.24

THE COWEN INSIGHT
The ~25.5% auto margin, >20% Model 3 margin, and the company's control of Opex and Capex were impressive. Management walked back its 10K/week production target and instead focused on hitting 7K, which could lead to lower production estimates from the Bulls for '19-20. Cash improvements bode well for short term debt repayments, but we remain concerned about competition, LT capex needs & valuation.

Jeffrey Osborne
646 562 1391
jeffrey.osborne@cowen.com
Consumer
Specialty Retail
China Risk Factors: We Rank China Risk Factors Across Our Sector...

THE COWEN INSIGHT

...& Analyze the Past to Inform the Future. China macroeconomic concerns, China tourism flow, & stepped-up enforcement on off-shore luxury purchases are significant 2H18 caution points. We analyzed: valuations in 2012 when China cracked down on gift giving practices, company diversification/strategy, & both China geographic and tourism exposure levels. From a stock perspective...

Oliver Chen, CFA
646 562 1424
oliver.chen@cowen.com

Capital Goods/Industrials
Trinity Industries
Expect Volatility as Guidance is Examined

OUTPERFORM (1)

Symbol: TRN
Price Target: $47.00
Price (10/24/2018): $33.54
Market Cap (MM): $4,913.6

THE COWEN INSIGHT

The midpoint of 2019 RemainCo EPS guidance seems to imply 38% growth if we assume 2H18 RemainCo EPS exceeds 1H18 RemainCo EPS by a similar rate to that at which our current 2H18 rail businesses EBIT exceeds our 1H18 rail businesses EBIT. Guidance may be examined in other ways, not necessarily leading to uniform conclusions. We expect stock volatility and look for more clarity on the call.

Matt Elkott
646 562 1409
matthew.elkott@cowen.com

Capital Goods/Industrials
United Parcel Service
Looming Tariffs Overshadow Improving Peak Trends

MARKET PERFORM (2)

Symbol: UPS
Price Target: $128.00
Price (10/24/2018): $107.93
Market Cap (MM): $92,711.9

THE COWEN INSIGHT

We believe it is likely UPS's experience during the peak shipping season will improve on a y/y basis as new sorting facilities come on line. US - China tariffs had a small impact on 3Q18 earnings, although uncertainty remains as we approach the January 1 tariffs. As a result, our 2019 EPS estimate moves slightly lower to $7.85 from $7.90 (consensus is $7.93).

Helane Becker
646 562 1399
helane.becker@cowen.com
Health Care

Vertex

Q3 In-Line, Triple Data On Track For Q4

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: VRTX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$200.00</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$163.09</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$41,679.3</td>
</tr>
</tbody>
</table>

**EPS $**

<table>
<thead>
<tr>
<th></th>
<th>2017A</th>
<th>2018E</th>
<th>2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$1.95</td>
<td>$3.80</td>
<td>$3.80</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$3.75</td>
<td>$4.40</td>
</tr>
<tr>
<td>Consensus</td>
<td>$1.95</td>
<td>$3.77</td>
<td>$4.68</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

VRTX reported Q3 CF franchise revenue of $784.5MM vs consensus of $781MM, non-GAAP EPS of $1.09 vs. consensus of $1.01, and reiterated 2018 guidance. Results from 2 Ph. III trials of VX-659 triples are on track for Q4 while data from ABBV's FALCON trial confirm that its lead triple will not be competitive. We expect VRTX to have industry-leading top-line growth thru ’23 and it remains a top pick.

Phil Nadeau, Ph.D.
646 562 1336
phil.nadeau@cowen.com

Technology, Media & Telecom

Visa

V F4Q18: Steady Growth

**OUTPERFORM (1)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NYSE: V</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$164.00</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>$134.26</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>$273,118.6</td>
</tr>
</tbody>
</table>

**EPS $**

<table>
<thead>
<tr>
<th></th>
<th>2018A</th>
<th>2019E</th>
<th>2020E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$4.61</td>
<td>$5.35</td>
<td>$6.22</td>
</tr>
<tr>
<td>Consensus</td>
<td>$4.61</td>
<td>$5.33</td>
<td>$6.19</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

V reported F4Q results that were largely in-line with our estimates. The company provided FY19 guidance that dovetails with Street expectations - reflecting a continuation of double digit growth. We expect guidance to be greeted positively by investors. We are modestly increasing our forward estimates. We reiterate our $164 PT and Outperform rating.

George Mihalos
646 562 1360
george.mihalos@cowen.com

Technology, Media & Telecom

Xilinx

A Port In The Storm

**MARKET PERFORM (2)**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>NASDAQ: XLNX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price Target</td>
<td>$81.00</td>
</tr>
<tr>
<td>Price (10/24/2018)</td>
<td>69.04</td>
</tr>
<tr>
<td>Market Cap (MM)</td>
<td>17,461.2</td>
</tr>
</tbody>
</table>

**EPS $**

<table>
<thead>
<tr>
<th></th>
<th>2018A</th>
<th>2019E</th>
<th>2020E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen</td>
<td>$3.24</td>
<td>$3.83</td>
<td>$4.26</td>
</tr>
<tr>
<td>Prior</td>
<td>-</td>
<td>$3.59</td>
<td>$4.06</td>
</tr>
<tr>
<td>Consensus</td>
<td>-</td>
<td>$3.28</td>
<td>$3.73</td>
</tr>
</tbody>
</table>

**THE COWEN INSIGHT**

Xilinx reported a significant beat/raise as early 5G investments were the largest of multiple upside drivers. Net, Xilinx printed a near pitch-perfect quarter despite an ugly semis backdrop and we expect shares to react accordingly. Trading at a large premium to peers, however, we see risk/reward as balanced and await further signs of datacenter traction. Maintain Market Perform, $81 target.

Matthew D. Ramsay
415 646 7373
matt.ramsay@cowen.com

**Link to Full Note**
Macro Commentary Today

WRG Macro Commentary

WRG Medical Devices

Med Tech & Mid-Terms: Agencies Likely Still More Impactful than Congress

THE COWEN INSIGHT

Med tech is likely to have minimal legislative risk in 2019, regardless of the election outcome. The regulatory agencies (CMS/FDA) are more important to watch and we predict both will continue to take deregulatory actions of particular benefit to digital health and telemedicine.

Eric Assaraf
202 868 5304
eric.assaraf@cowen.com

Link to Full Note

WRG Macro Commentary

WRG Washington Strategy

Washington Pressure Gauge: 2018 Policy Calendar One-Pager

THE COWEN INSIGHT

Midterms in 12 days.

Senate & House elections in almost different countries: rural v. suburban - geography is destiny this cycle.

Main NAFTA takeaway: tariffs worked & still in place.

25% tariff on autos & parts likely in Q4 - implementation next year - same with more China tariffs.

Chris Krueger
202 868 5307
chris.krueger@cowen.com

Link to Full Note

Upcoming Conferences

POST-ELECTION POW-WOW
November 12-13, 2018 | Washington, D.C.

8TH ANNUAL ENERGY & NATURAL RESOURCES CONFERENCE
December 4-5, 2018 | New York, NY

5TH ANNUAL NETWORKING AND CYBERSECURITY SUMMIT
December 11-12, 2018
New York, NY
## Points Of Contact

### Product Management

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drew Payne</td>
<td>Product Manager</td>
<td>646 562 1579</td>
</tr>
<tr>
<td>Alexander Katzman</td>
<td></td>
<td>646 562 1597</td>
</tr>
<tr>
<td>Kyle Flynn</td>
<td></td>
<td>646 562 1542</td>
</tr>
</tbody>
</table>

### Trading Desk

<table>
<thead>
<tr>
<th>Location</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>New York</td>
<td>646 562 1500</td>
</tr>
<tr>
<td>Boston</td>
<td>617.946.3890</td>
</tr>
</tbody>
</table>
Important Disclosures and Information Relating to Cowen Washington Research Group

Cowan Washington Research Group produces commentaries on political, economic or market conditions. Commentaries produced by Cowen Washington Research Group are not intended as research reports as defined in FINRA Rule 2241 Research Analysts and Research Reports or FINRA Rule 2242 Debt Research Analysts and Debt Research Reports. Sections of this report noted as authored by Cowen Washington Research Group have not been prepared, are not intended, and should not be interpreted as a research report or investment recommendation regarding securities of any company. Investors should not consider purchasing or selling securities based upon any information contained in sections of the report denoted as authored by Cowen Washington Research Group.

Analyst Certification

Each author of this research report hereby certifies that (i) the views expressed in the research report accurately reflect his or her personal views about any and all of the subject securities or issuers, and (ii) no part of his or her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed in this report.

Important Disclosures

This report constitutes a compendium report (covers six or more subject companies). As such, Cowen and Company, LLC chooses to provide specific disclosures for the companies mentioned by reference. To access current disclosures for the all companies in this report, clients should refer to https://cowen.bluematrix.com/sellside/Disclosures.action or contact your Cowen and Company, LLC representative for additional information.

Cowan and Company, LLC compensates research analysts for activities and services intended to benefit the firm’s investor clients. Individual compensation determinations for research analysts, including the author(s) of this report, are based on a variety of factors, including the overall profitability of the firm and the total revenue derived from all sources, including revenues from investment banking, sales and trading or principal trading revenues. Cowen and Company, LLC does not compensate research analysts based on specific investment banking transactions or specific sales and trading or principal trading revenues.

Disclaimer

Our research reports are simultaneously available to all clients are on our client website. Research reports are for our clients only. Not all research reports are disseminated, e-mailed or made available to third-party aggregators. Cowen and Company, LLC is not responsible for the redistribution of research by third party aggregators. Selected research reports are available in printed form in addition to an electronic form. All published research reports can be obtained on the firm’s client website, https://cowenlibrary.bluematrix.com/client/library.jsp.

The information, opinions, estimates and forecasts are as of the date of this report and subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Research reports are published at irregular intervals as appropriate in the analyst’s judgement.

Further information on subject securities may be obtained from our offices. This research report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. Other than disclosures relating to Cowen and Company, LLC, the information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice. The opinions and recommendations herein do not take into account individual client circumstances, objectives or needs and are not intended as recommendations of investment strategy. The recipients of this report must make their own independent decisions regarding any securities subject to this research report. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. To the extent that this report discusses any legal proceedings or issues, it has not been prepared to express or intended to express any legal conclusion, opinion or advice. Our salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed in our research. Our principal trading area and investing businesses may make investment decisions that are inconsistent with recommendations or views expressed in our research. Cowen and Company, LLC maintains physical, electronic and procedural information barriers to address the flow of information between and among departments within Cowen and Company, LLC in order to prevent and avoid conflicts of interest with respect to analyst recommendations.

For important disclosures regarding the companies that are the subject of this research report, please contact Compliance Department, Cowen and Company, LLC. 599 Lexington Avenue, 20th Floor. New York, NY 10022. In addition, the same important disclosures, with the exception of the valuation methods and risks, are available on the Firm’s disclosure website at https://cowen.bluematrix.com/sellside/Disclosures.action.

Equity Research Price Targets: Cowen and Company, LLC assigns price targets on all companies covered in equity research unless noted otherwise. The equity research price target for an issuer’s stock represents the value that the analyst reasonably expects the stock to reach over a performance period of twelve months. Any price targets in equity securities in this report should be considered in the context of all previously published Cowen and Company, LLC equity research reports (including the disclosures in any such equity report or on the Firm’s disclosure website), which may or may not include equity research price targets, as well as developments relating to the issuer, its industry and the financial markets. For equity research price target valuation methodology and risks associated with the achievement of any given equity research price target, please see the analyst’s equity research report publishing such targets.

Cowan Credit Research and Trading: Due to the nature of the fixed income market, the issuers or debt securities of the issuers discussed in “Cowan Credit Research and Trading” research reports do not assign ratings and price targets and may not be continuously followed. Accordingly, investors must regard such branded reports as providing stand-alone analysis and reflecting the analyst’s opinion as of the date of the report and should not expect continuing analysis or additional reports relating to such issuers or debt securities of the issuers.

From time to time “Cowan Credit Research and Trading” research analysts provide investment recommendations on securities that are the subject of this report. These recommendations are intended only as of the time and date of publication and only within the parameters specified in each individual report. “Cowan Credit Research and Trading” investment recommendations are made strictly on a case-by-case basis, and no recommendation is provided as part of an overarching rating system or other set of consistently applied benchmarks. The views expressed in this report may differ from the views offered in the firm’s equity research reports prepared for our clients.

Notice to UK Investors: This publication is produced by Cowen and Company, LLC which is regulated in the United States by FINRA. It is to be communicated only to persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It must not be further transmitted to any other person without our consent.

Notice to European Union Investors: Individuals producing recommendations are required to obtain certain licenses by the Financial Regulatory Authority (FINRA). You can review the author’s current licensing status and history, employment history and, if any, reported regulatory, customer dispute, criminal and other matters via “Brokercheck by FINRA” at http://
brokercheck.finra.org/. An individual’s licensing status with FINRA should not be construed as an endorsement by FINRA. General biographical information is also available for each Research Analyst at www.cowen.com.

Additionally, the complete preceding 12-month recommendations history related to recommendation in this research report is available at https://cowen.bluematrix.com/sellside/Disclosures.action

The recommendation contained in this report was produced at October 25, 2018, 07:00 ET. and disseminated at October 25, 2018, 07:00 ET.

Copyright, User Agreement and other general information related to this report

© 2018 Cowen and Company, LLC. All rights reserved. Member NYSE, FINRA and SIPC. This research report is prepared for the exclusive use of Cowen clients and may not be reproduced, displayed, modified, distributed, transmitted or disclosed, in whole or in part, or in any form or manner, to others outside your organization without the express prior written consent of Cowen. Cowen research reports are distributed simultaneously to all clients eligible to receive such research reports. Any unauthorized use or disclosure is prohibited. Receipt and/or review of this research constitutes your agreement not to reproduce, display, modify, distribute, transmit, or disclose to others outside your organization. All Cowen trademarks displayed in this report are owned by Cowen and may not be used without its prior written consent.

Cowen and Company, LLC. New York 646 562 1010 Boston 617 946 3700 San Francisco 415 646 7200 Chicago 312 577 2240 Cleveland 440 331 3531 Atlanta 866 544 7009 Stamford 646 616 3000 Washington, D.C. 202 868 5300 London (affiliate) 44 207 071 7500

COWEN AND COMPANY EQUITY RESEARCH RATING DEFINITIONS

Outperform (1): The stock is expected to achieve a total positive return of at least 15% over the next 12 months

Market Perform (2): The stock is expected to have a total return that falls between the parameters of an Outperform and Underperform over the next 12 months

Underperform (3): Stock is expected to achieve a total negative return of at least 10% over the next 12 months

Assumption: The expected total return calculation includes anticipated dividend yield

Cowen and Company Equity Research Rating Distribution

<table>
<thead>
<tr>
<th>Distribution of Ratings/Investment Banking Services (IB) as of 09/30/18</th>
<th>Count</th>
<th>Ratings Distribution</th>
<th>IB Services/Past 12 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buy (a)</td>
<td>472</td>
<td>63.44%</td>
<td>115</td>
</tr>
<tr>
<td>Hold (b)</td>
<td>266</td>
<td>35.75%</td>
<td>23</td>
</tr>
<tr>
<td>Sell (c)</td>
<td>6</td>
<td>0.81%</td>
<td>0</td>
</tr>
</tbody>
</table>

(a) Corresponds to “Outperform” rated stocks as defined in Cowen and Company, LLC’s equity research rating definitions. (b) Corresponds to “Market Perform” as defined in Cowen and Company, LLC’s equity research ratings definitions. (c) Corresponds to “Underperform” as defined in Cowen and Company, LLC’s equity research ratings definitions. Cowen and Company Equity Research Rating Distribution Table does not include any company for which the equity research rating is currently suspended or any debt security followed by Cowen Credit Research and Trading.

Note: “Buy”, “Hold” and “Sell” are not terms that Cowen and Company, LLC uses in its ratings system and should not be construed as investment options. Rather, these ratings terms are used illustratively to comply with FINRA regulation.
POINTS OF CONTACT

Reaching Cowen

Main U.S. Locations

New York
599 Lexington Avenue
New York, NY 10022
646 562 1010
800 221 5616

Atlanta
3399 Peachtree Road NE
Suite 417
Atlanta, GA 30326
866 544 7009

Boston
Two International Place
Boston, MA 02110
617 946 3700
800 343 7068

Chicago
181 West Madison Street
Suite 3135
Chicago, IL 60602
312 577 2240

Cleveland
20006 Detroit Road
Suite 100
Rocky River, OH 44116
440 331 3531

Stamford
262 Harbor Drive
Stamford, CT 06902
646 616 3000

San Francisco
One Maritime Plaza, 9th Floor
San Francisco, CA 94111
415 646 7200
800 858 9316

Washington, D.C.
2900 K Street, NW
Suite 520
Washington, DC 20007
202 868 5300

International Location

Cowen International Limited
London
1 Snowden Street - 11th Floor
London EC2A 2DQ
United Kingdom
44 20 7071 7500